Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Strikes Deal For Amira Compounds
February 11, 2008
| A version of this story appeared in
Volume 86, Issue 6
GlaxoSmithKline has agreed to develop and market Amira Pharmaceuticals' FLAP (5-lipoxygenase activating protein) inhibitors for treating respiratory and cardiovascular diseases. San Diego-based Amira could receive up to $425 million in upfront fees and milestone payments, along with royalties on any commercialized products. Initial work will focus on AM103, an oral, nonsteroidal compound for treating asthma that just successfully completed Phase I clinical trials. Founded in mid-2005 and run by former drug industry executives and researchers, Amira already has a research collaboration with Roche and has raised $40 million in private equity financing.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter